Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.

Objective To determine the pharmacokinetics and hemodynamic effects of trazodone after IV and oral administration in dogs and bioavailability after oral administration. Animals-6 adult Beagles. Procedures Dogs received trazodone HCl (8 mg/kg) orally and IV in a randomized controlled crossover design. Blood samples were collected at various times after administration. Heart rates and indirectly measured blood pressures of dogs and plasma concentrations and pharmacokinetics of trazodone were determined. Results Following IV administration, the mean +/- SD elimination half-life, apparent volume of distribution, and plasma total body clearance were 169 +/- 53 minutes, 2.53 +/- 0.47 L/kg, and 11.15 +/- 3.56 mL/min/kg, respectively. Following oral administration, the mean SD elimination half-life and absolute bioavailability were 166 +/- 47 minutes and 84.6 +/- 13.2%, respectively. Maximum plasma concentration following oral administration was 1.3 +/- 0.5 mu g/mL, and time to maximum plasma concentration was 445 +/- 271 minutes. After IV administration, all dogs immediately developed transient tachycardia (184.3 +/- 8.0 beats/min), and 3 of 6 dogs developed aggression. Increase in heart rate was significantly associated with increase in plasma drug concentration following IV administration. Conclusions and Clinical Relevance Results of this study indicated oral administration of trazodone resulted in acceptable absolute bioavailability, with substantial variability in time to maximum plasma concentration. Individualized approaches in dosing intervals may be necessary for dogs receiving oral trazodone. An orally administered dose of 8 mg/kg was well tolerated in dogs; IV administration of a dose of 8 mg/kg caused substantial adverse effects, including tachycardia and behavior disinhibition.